JPMorgan analyst Lilia-Celine Lozada raised the firm’s price target on AtriCure (ATRC) to $51 from $40 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect the Q4 pre-announcement and 2025 guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- Atricure, Inc. (ATRC) Q4 Earnings Cheat Sheet
- AtriCure price target raised to $51 from $40 at Needham
- AtriCure sees FY25 revenue $517M-$527M, consensus $522.81M
- AtriCure reports preliminary Q4 revenue $124.3M, consensus $119.85M
- AtriCure ups FY24 revenue view to $465.3M from $459M-$462M, consensus $460.89M